The Latest
-
Illustration: Deena So Oteh for Industry Dive/PharmaVoice
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
-
Drew Angerer via Getty Images
Pfizer CEO Albert Bourla led Big Pharma bonus payouts over 5 years — but he’s no Elon Musk
A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.
-
Tinnakorn Jorruang via Getty Images
How pharma marketers can reclaim the drug pricing narrative
As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.
-
Mario Tama / Getty via Getty Images
Q&AInside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant
Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.
-
iStock via Getty Images
Do humans have a place in pharma’s AI future?
From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.
-
Stock via Getty Images
Q&A // First 90 DaysWhy Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’
The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.
-
Photo illustration: Industry Dive; Getty Images
The PharmaVoice 100: Standout execs
Leaders who’ve created unique strategies for thriving amid the heavy headwinds facing the industry.
-
Stock via Getty Images
Elderly exclusion: Clinical trials still fall short enrolling older adults
Despite high rates of disease in older populations, systemic issues are keeping them out of research studies.
-
Stock via Getty Images
ProfileThree years after an FDA rejection, DBV sees a path for its peanut patch
Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says the company’s topical skin patch could be a game-changing option for patients.
-
iStock via Getty Images
Q&AAs the opioid crisis seethes, a long-lasting treatment could offer new ammunition
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
-
Jos Everts via Getty Images via Getty Images
-
Rebecca Pifer/PharmaVoice
PBMs, PhRMA trade blame over drug costs in House hearing
Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second PBM hearing on Tuesday.
-
iStock via Getty Images
Endangered horseshoe crabs could lead the charge in pharma’s animal-free future
An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.
-
iStock via Getty Images
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
-
Courtesy of Sanofi
O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad
The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups.
-
saengsuriya13 via Getty Images
Q&AIn the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
-
Stock via Getty Images
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
-
Stock via Getty Images
A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say
A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.
-
Permission granted by Regeneron
A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups
The biotech’s chief financial officer Robert Landry is retiring in February.
-
Igor Kutyaev via Getty Images
Ex-Sanofi executive Sibold joins Madrigal as new CEO
Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.
-
Stock via Getty Images
Biotech SpotlightImmuneering takes aim at cancer’s ‘superhighway’
After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.
-
Stock via Getty Images
In advocates’ ongoing push for superbug funding, ‘$6 billion is nothing’
The PASTEUR Act is likely heading for another legislative blow, but advocates say they see a future for the mechanism to fund the battle against antimicrobial resistance.
-
Permission granted by Armon Sharei
Profile‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride
Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.
-
Stock via Getty Images
Pharma faces a slew of leadership shakeups
Biogen, Sanofi, Bristol Myers Squibb and more have all recently announced major executive changes.
-
Courtesy of Empress Therapeutics
ProfileWhy this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery
Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.
